stockrowSanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Sanofi (SNY) Shares outstanding
Sanofi's shares outstanding at the end of fiscal 2025 was $2.5B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $2.4B. Over the past ten years it has ranged from $2.5B (fiscal 2025) to $2.6B (fiscal 2015) — the current reading is the lowest in ten years. Sanofi ranks 5th of 20 Drug Manufacturers General companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $2.5B | (2.43%) |
| FY2024 | $2.5B | (0.02%) |
| FY2023 | $2.5B | (0.04%) |
| FY2022 | $2.5B | (0.08%) |
| FY2021 | $2.5B | (0.17%) |
| FY2020 | $2.5B | 0.24% |
| FY2019 | $2.5B | 0.15% |
| FY2018 | $2.5B | (0.92%) |
| FY2017 | $2.5B | (2.25%) |
| FY2016 | $2.6B | (1.87%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $2.4B | 0.28% |
| Jun 2026 | $2.4B | (0.63%) |
| Mar 2026 | $2.4B | (1.75%) |
| Dec 2025 | $2.5B | 0.62% |
| 39 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| PFE Pfizer Inc. compare | $5.8B |
| NVO Novo Nordisk A/S compare | $4.4B |
| SNY Sanofi | $2.4B |
| BMY Bristol Myers Squibb Company compare | $2.1B |
| GSK GSK PLC Sponsored ADR compare | $2.0B |
| NVS Novartis AG compare | $1.9B |
| AZN AstraZeneca PLC compare | $1.6B |
| GILD Gilead Sciences, Inc. compare | $1.3B |
| AMGN Amgen Inc. compare | $546.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on SNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement